BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36063968)

  • 1. Non-invasive tests for clinically significant portal hypertension after HCV cure.
    Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
    J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    Jachs M; Sandmann L; Hartl L; Tergast T; Schwarz M; Bauer DJM; Balcar L; Ehrenbauer A; Hofer BS; Cornberg M; Lenzen H; Deterding K; Trauner M; Mandorfer M; Wedemeyer H; Reiberger T; Maasoumy B
    J Hepatol; 2024 Mar; ():. PubMed ID: 38479612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
    Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
    Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
    Jindal A; Agarwal S; Sharma S; Kumar M; Saraya A; Sarin SK
    Dig Dis Sci; 2023 May; 68(5):2149-2157. PubMed ID: 36562888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension.
    Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Balcar L; Semmler G; Stättermayer AF; Pinter M; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1854-1863.e10. PubMed ID: 36244661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography.
    Podrug K; Trkulja V; Zelenika M; Bokun T; Madir A; Kanizaj TF; O'Beirne J; Grgurevic I
    Dig Dis Sci; 2022 Jul; 67(7):3327-3332. PubMed ID: 34739624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
    Semmler G; Alonso López S; Pons M; Lens S; Dajti E; Griemsmann M; Zanetto A; Burghart L; Hametner-Schreil S; Hartl L; Manzano M; Rodriguez-Tajes S; Zanaga P; Schwarz M; Gutierrez ML; Jachs M; Pocurull A; Polo B; Ecker D; Mateos B; Izquierdo S; Real Y; Ahumada A; Bauer DJM; Mauz JB; Casanova-Cabral M; Gschwantler M; Russo FP; Azzaroli F; Maasoumy B; Reiberger T; Forns X; Genesca J; Bañares R; Mandorfer M;
    J Hepatol; 2024 Mar; ():. PubMed ID: 38521170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
    Paternostro R; Kwanten WJ; Hofer BS; Semmler G; Bagdadi A; Luzko I; Hernández-Gea V; Graupera I; García-Pagán JC; Saltini D; Indulti F; Schepis F; Moga L; Rautou PE; Llop E; Téllez L; Albillos A; Fortea JI; Puente A; Tosetti G; Primignani M; Zipprich A; Vuille-Lessard E; Berzigotti A; Taru MG; Taru V; Procopet B; Jansen C; Praktiknjo M; Gu W; Trebicka J; Ibanez-Samaniego L; Bañares R; Rivera-Esteban J; Pericas JM; Genesca J; Alvarado E; Villanueva C; Larrue H; Bureau C; Laleman W; Ardevol A; Masnou H; Vanwolleghem T; Trauner M; Mandorfer M; Francque S; Reiberger T;
    J Hepatol; 2024 May; ():. PubMed ID: 38823501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease.
    Semmler G; Binter T; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Gavasso S; Chromy D; Bauer DJM; Simbrunner B; Scheiner B; Bucsics T; Stättermayer AF; Pinter M; Steindl-Munda P; Schöfl R; Russo FP; Simioni P; Trauner M; Ferenci P; Reiberger T; Mandorfer M
    Hepatology; 2021 Apr; 73(4):1275-1289. PubMed ID: 32659847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension.
    Semmler G; Hartl L; Mendoza YP; Simbrunner B; Jachs M; Balcar L; Schwarz M; Hofer BS; Fritz L; Schedlbauer A; Stopfer K; Neumayer D; Maurer J; Szymanski R; Meyer EL; Scheiner B; Quehenberger P; Trauner M; Aigner E; Berzigotti A; Reiberger T; Mandorfer M
    Hepatology; 2024 Mar; ():. PubMed ID: 38447034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.
    Liu C; Li J; Wong YJ; Xie Q; Hirooka M; Enomoto H; Kim TH; Hanafy AS; He R; Koizumi Y; Hiasa Y; Nishimura T; Iijima H; Jung YK; Yim HJ; Ma J; Zeng QL; Sarin SK; Qi X
    Hepatol Int; 2022 Oct; 16(5):1105-1115. PubMed ID: 35606627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
    Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
    Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
    Reiniš J; Petrenko O; Simbrunner B; Hofer BS; Schepis F; Scoppettuolo M; Saltini D; Indulti F; Guasconi T; Albillos A; Téllez L; Villanueva C; Brujats A; Garcia-Pagan JC; Perez-Campuzano V; Hernández-Gea V; Rautou PE; Moga L; Vanwolleghem T; Kwanten WJ; Francque S; Trebicka J; Gu W; Ferstl PG; Gluud LL; Bendtsen F; Møller S; Kubicek S; Mandorfer M; Reiberger T
    J Hepatol; 2023 Feb; 78(2):390-400. PubMed ID: 36152767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography.
    Grgurevic I; Madir A; Trkulja V; Bozin T; Aralica G; Podrug K; Mikolaševic I; Tsochatzis E; O'Beirne J; Pinzani M
    Eur J Clin Invest; 2022 Jun; 52(6):e13750. PubMed ID: 35040495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of Baveno VII criteria for clinically significant portal hypertension by two-dimensional shear wave elastography.
    He R; Liu C; Grgurevic I; Guo Y; Xu H; Liu J; Liu Y; Wang X; Shi H; Madir A; Podrug K; Zhu Y; Hua Y; Wang K; Wen J; Su M; Zhang Q; Li J; Qi X
    Hepatol Int; 2024 Jun; 18(3):1020-1028. PubMed ID: 38740698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma.
    Souhami A; Sartoris R; Rautou PE; Cauchy F; Bouattour M; Durand F; Giannelli V; Gigante E; Castera L; Valla D; Soubrane O; Vilgrain V; Ronot M
    JHEP Rep; 2020 Oct; 2(5):100147. PubMed ID: 32885156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.